RXFP4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL30571163	0.56	6/20
SCHEMBL13227619	0.43	6/20
SCHEMBL13227611	0.43	6/20
SCHEMBL13227631	0.43	6/20
SCHEMBL20564393	0.39	6/20
SCHEMBL23295919	0.39	6/20
SCHEMBL23295928	0.39	6/20
SCHEMBL14274735	0.38	6/20
SCHEMBL14274732	0.38	6/20
SCHEMBL14274725	0.38	6/20
SCHEMBL14274723	0.38	6/20
SCHEMBL14274739	0.38	6/20
SCHEMBL29689331	0.62	5/20
SCHEMBL28586826	0.61	5/20
Ularitide (SCHEMBL27908491)	0.61	5/20
Ularitide (SCHEMBL29484210)	0.61	5/20
SCHEMBL29389059	0.61	5/20
SCHEMBL30712918	0.61	5/20
SCHEMBL29397243	0.60	5/20
Lactoferricin (SCHEMBL29376740)	0.60	5/20

Clinical trials — most relevant to RXFP4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
A Study Of The Usage Of Statins In A Community Heart Failure Population	PHASE4	COMPLETED
Linagliptin's Effect on CD34+ Stem Cells	PHASE4	COMPLETED
Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients	PHASE4	COMPLETED
Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)	PHASE4	RECRUITING
Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure.	PHASE3	UNKNOWN
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)	PHASE3	COMPLETED
Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia	PHASE2	RECRUITING
Effects of Exenatide on Hypothalamic Obesity	PHASE1/PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia	PHASE2	COMPLETED
Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure	PHASE2	COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
The Role of Phosphodiesterase Inhibitors in Incretin Secretion	PHASE1	COMPLETED
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease	EARLY_PHASE1	RECRUITING
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)	nan	COMPLETED
Blocking of the Gut Hormone Receptor for Glucagon-like Peptide 2 (GLP-2) by the GLP-2 Receptor Antagonist GLP-2(3-33)	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Relaxin Measurement in Different Endometrial Preparation Approaches for Frozen Embryo Transfer	nan	RECRUITING
Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma	nan	COMPLETED
Effect of Supplement on Appetite and GLP-1	nan	COMPLETED
Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention	nan	NOT_YET_RECRUITING
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
Purinergic Signaling and the Postmenopausal Heart	nan	RECRUITING
Gastroparesis Registry 3	nan	COMPLETED
Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy	nan	COMPLETED
The Effect of Weekly Semaglutide Treatment on Energy Expenditure	nan	COMPLETED
Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases	nan	COMPLETED
Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome	nan	COMPLETED
Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a RXFP4 binder may also engage these)

Protein	Name	Similarity
Q7TQP4	—	0.990	Q7TQP4 →
O00155	—	0.985	O00155 →
P0C5I1	—	0.985	P0C5I1 →
GALR2	Galanin receptor type 2	0.984	landscape →
Q920E0	—	0.979	Q920E0 →
Q9Z2J6	—	0.978	Q9Z2J6 →
O08726	—	0.978	O08726 →
PTGDR2	Prostaglandin D2 receptor 2	0.978	landscape →
HTR6	5-hydroxytryptamine receptor 6	0.978	landscape →
Q95252	—	0.977	Q95252 →
Q6XKD3	—	0.977	Q6XKD3 →
O88854	—	0.976	O88854 →
ADRB3	Beta-3 adrenergic receptor	0.976	landscape →
Q76JU9	—	0.976	Q76JU9 →
Q8K3T4	—	0.975	Q8K3T4 →
Q3ZC80	—	0.975	Q3ZC80 →
LPAR5	Lysophosphatidic acid receptor 5	0.975	landscape →
P31388	—	0.975	P31388 →
O00270	—	0.974	O00270 →
Q9R1C8	—	0.973	Q9R1C8 →
Q8BW93	—	0.973	Q8BW93 →
A0A6I8PUB9	—	0.973	A0A6I8PUB9 →
P2RY11	P2Y purinoceptor 11	0.973	landscape →
O09027	—	0.973	O09027 →
O88634	—	0.972	O88634 →
P31392	—	0.971	P31392 →
Q149R9	—	0.971	Q149R9 →
P43142	—	0.971	P43142 →
Q9JL21	—	0.971	Q9JL21 →
Q9XT58	—	0.971	Q9XT58 →